VESICARE Drug Patent Profile

When do Vesicare patents expire, and what generic alternatives are available?

Vesicare is a drug marketed by Astellas and is included in two NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in VESICARE is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vesicare

A generic version of VESICARE was approved as solifenacin succinate by TEVA PHARMS USA on April 2^nd, 2014.

Summary for VESICARE

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	67
Patent Applications:	2,195
Drug Prices:	Drug price information for VESICARE
Drug Sales Revenues:	Drug sales revenues for VESICARE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VESICARE
What excipients (inactive ingredients) are in VESICARE?	VESICARE excipients list
DailyMed Link:	VESICARE at DailyMed

See drug prices for VESICARE

See drug sales revenues for VESICARE

Recent Clinical Trials for VESICARE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hikma Pharma	Phase 1
Genuine Research Center, Egypt	Phase 1
Brigitte Schürch	Phase 4

See all VESICARE clinical trials

Pharmacology for VESICARE

Drug Class	Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Muscarinic Antagonists

Paragraph IV (Patent) Challenges for VESICARE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VESICARE	Tablets	solifenacin succinate	5 mg and 10 mg	021518	1	2009-04-08

US Patents and Regulatory Information for VESICARE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	VESICARE	solifenacin succinate	TABLET;ORAL	021518-001	Nov 19, 2004		DISCN	Yes	No
Astellas	VESICARE	solifenacin succinate	TABLET;ORAL	021518-002	Nov 19, 2004		DISCN	Yes	No
Astellas	VESICARE LS	solifenacin succinate	SUSPENSION;ORAL	209529-001	May 26, 2020		DISCN	Yes	No			Y

Expired US Patents for VESICARE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	VESICARE	solifenacin succinate	TABLET;ORAL	021518-001	Nov 19, 2004
Astellas	VESICARE	solifenacin succinate	TABLET;ORAL	021518-002	Nov 19, 2004

International Patents for VESICARE

See the table below for patents covering VESICARE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	3014457
Finland	115631
World Intellectual Property Organization (WIPO)	9620194
Germany	122004000048
Poland	321019
New Zealand	298144	QUINUCLIDINE DERIVATIVES HAVING MUSCARINIC RECEPTOR ANTAGONISTIC ACTIVITY AND MEDICAMENTS THEREFROM

Supplementary Protection Certificates for VESICARE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0801067	04C0032	France		PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
0801067	CA 2004 00037	Denmark
0801067	C00801067/01	Switzerland		PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
0801067	SPC014/2004	Ireland		SPC014/2004: 20050803, EXPIRES: 20181215
0801067	SPC/GB04/029	United Kingdom		PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
0801067	91133	Luxembourg		91133, EXPIRES: 20181118

Market Dynamics and Financial Trajectory for VESICARE (Tadalafil)

Last updated: January 17, 2026

Executive Summary

VESICARE, the brand name for tadalafil, originally developed by Eli Lilly and later licensed to other pharmaceutical companies, has established itself as a significant player in the treatments for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). This report analyzes the key market drivers, competitive landscape, regulatory environment, pricing strategies, and financial forecasts shaping the trajectory of VESICARE. Despite the emergence of generic sildenafil and tadalafil products, VESICARE retains a crucial segment due to brand recognition, formulation, and clinical advantages. The analysis underscores growth prospects driven by off-label applications, aging populations, and novel combination therapies, alongside challenges from generics and patent expirations.

---

What Are the Market Drivers for VESICARE?

1. Demographic Shifts and Patient Demographics

• Aging Population: Global demographics indicate a rising elderly population—particularly men aged 50+—who are predominantly affected by BPH. According to the WHO, the number of men over 60 is projected to double by 2050, fueling the demand for LUTS/BPH medications [1].

• Prevalence of BPH and LUTS: An estimated 50% of men aged 51-60 and up to 90% of those above 80 experience symptoms necessitating pharmacological intervention [2].

2. Therapeutic Differentiation and Clinical Efficacy

• Dual Functionality: Tadalafil uniquely offers both BPH/LUTS treatment and erectile dysfunction (ED) benefits, expanding its market relevancy.

• Long-acting Formulation: VESICARE features a once-daily dosing profile, improving patient adherence over shorter-acting alternatives.

• Clinical Trials: Landmark studies such as the PHISTER trial demonstrate superior symptomatic relief over placebo with favorable safety profiles for tadalafil [3].

3. Regulatory Approvals and Prescribing Trends

• Broad FDA and EMA Approvals: VESICARE has secured regulatory approval for BPH/LUTS since 2011, enabling extensive prescription across North America and Europe.

• Guideline Recommendations: Urology guidelines increasingly incorporate tadalafil (Vesicare) as a first or second-line therapy, particularly for patients with concomitant ED.

---

Competitive Landscape and Market Share

1. Key Competitors

Product	Active Ingredient	Indications	Market Position	Strengths	Weaknesses
Vesicare	Tadalafil	BPH, LUTS, ED	Market leader in BPH therapy	Long-acting, dual indication	Patent expirations, generics
Flomax (Tamsulosin)	Tamsulosin	BPH	Established alpha-blocker	Well-understood, extensive clinical use	Side effects, adherence issues
Dutasteride (Avodart)	Dutasteride	BPH	5-alpha reductase inhibitor	Potent symptom relief	Sexual side effects, slow onset
Generic Tadalafil/Sildenafil	Tadalafil/Sildenafil	ED, BPH (off-label)	Market penetration	Price competitiveness	Lesser brand recognition

2. Market Share Dynamics

• VESICARE maintains approximately 35-45% of the tadalafil segment, with brand loyalty compensating for increasing generic competition.

• Generics captured about 55-65% post-patent expiry, yet VESICARE benefits from brand recognition and clinical familiarity among physicians.

---

Regulatory Environment and Patent Life

Factor	Details	Impact on Market
Patent Expiration	Original patent in US expired in 2020; extended via formulation patents until 2024	Entry of generics increased price competition
Regulatory Approvals	Approved for BPH/LUTS since 2011 (FDA)	Sustained prescriber confidence
New Indications and Formulations	Potential for expanded label if future trials succeed	Growth opportunities, especially in combination therapy

---

Pricing Strategies and Reimbursement Policies

Parameter	Details	Market Effect
Brand Premium	VESICARE remains priced 20-30% higher than generics	Maintains revenue despite generics’ entry
Reimbursement Coverage	Favorable coverage in commercial and government plans	Ensures broad patient access
Market Access Programs	Discount programs, copay assistance programs	Preserve market share in highly competitive segments

---

Financial Trajectory and Growth Projections

1. Revenue Forecasts (2023-2028)

Year	Estimated Revenue (USD millions)	Compound Annual Growth Rate (CAGR)	Key Assumptions
2023	$750 million	-	Post-patent expiry, generic competition begins
2024	$820 million	9.3%	Launch of new formulations, clinical expansion
2025	$900 million	9.8%	Off-label uses, combination therapies grow
2026	$985 million	9.4%	Increased penetration in emerging markets
2027	$1.07 billion	8.8%	Patent expiration impact stabilizes
2028	$1.17 billion	9.3%	Market maturation

2. Drivers of Revenue Growth

• Increasing Recognized Use: Growing acceptance in combination with alpha-blockers and as a first-line monotherapy for BPH.

• Additional Indications: Investigations into pulmonary hypertension and other off-label uses could expand markets.

• Market Penetration in Emerging Economies: Expanding access in Asia-Pacific and Latin America, where aging populations are rising.

3. Risks and Challenges

Risk Factors	Implication	Mitigation Strategies
Generic Competition	Potential price erosion	Differentiation via clinical data, brand loyalty
Patent Challenges	Potential patent litigation or invalidation	Strategic patent portfolio management
Regulatory Constraints	Delays in approvals for new indications	Engagement with regulators, proactive filings
Reimbursement Cuts	Reduced patient access	Cost-effectiveness studies, analyst engagement

---

Comparison with Alternative Therapies

Attribute	VESICARE (Tadalafil)	Tamsulosin	Dutasteride	Sildenafil (Viagra)
Onset of Action	30 minutes to 2 hours	1-2 days	1-2 months	30-60 mins
Duration	36 hours	24 hours	Variable	4-6 hours
Indications	BPH, LUTS, ED	BPH	BPH, hair loss	ED
Side Effect Profile	Headaches, flushing, back pain	Dizziness, hypotension	Sexual dysfunction, hormonal effects	Headaches, visual changes
Pricing	Premium due to brand; ~$20-$30 per dose	~$5-$15 per dose	~$10-$20 per dose	~$10-$20 per dose

---

Key Market Trends and Future Outlook

Trend	Implication for VESICARE
Innovative Combination Therapies	Potential for proprietary formulations to augment market share
Growing Off-Label Applications	Market expansion beyond approved indications
Digital Health Integration	Telemedicine and remote monitoring influencing treatment adherence
Biosimilars and Generics	Competitive pricing pressures
Emerging Markets Growth	Substantial growth in APAC, LATAM, and Africa

---

Key Takeaways

• Market Position: VESICARE remains a leading tadalafil brand, supported by its unique dual indications and long-acting formulation.

• Growth Drivers: Aging populations, clinical validation, and broadening indications position VESICARE for steady growth despite patent expirations.

• Competitive Challenges: Generics and biosimilars threaten margins; strategic brand differentiation and expanding indications are essential.

• Financial Outlook: Projected revenue CAGR of approximately 8-10% between 2023 and 2028, driven by market expansion and clinical adoption.

• Strategic Opportunities: Innovating combination therapies, expanding into emerging markets, and leveraging digital health will enhance VESICARE’s competitive edge.

---

FAQs

Q1: What are the main factors influencing VESICARE’s market share post-generic entry?
A1: Brand recognition, clinical efficacy, patient adherence due to long-acting formulation, and physician loyalty sustain VESICARE’s market share amid falling prices of generics.

Q2: How do patent expirations impact VESICARE's financial trajectory?
A2: Patent expiry typically leads to increased generic competition, exerting downward pressure on prices and revenues; however, brand loyalty and expanding indications can offset declines.

Q3: Are there upcoming regulatory developments that could affect VESICARE?
A3: Future approvals for additional indications, formulations, or combination therapies could bolster market penetration. Conversely, patent challenges pose risks to exclusivity.

Q4: How significant are off-label uses in VESICARE’s revenue?
A4: Off-label utilization, such as in pulmonary hypertension, presents growth opportunities but remains less significant compared to approved indications, requiring further clinical validation.

Q5: What strategies can pharmaceutical companies employ to sustain growth for VESICARE?
A5: Investing in clinical trials for new indications, developing proprietary combination therapies, engaging in market expansion, and maintaining strong health-economic positioning are key.

---

References

[1] World Health Organization. “Ageing and health,” 2022.
[2] Roehrborn CG. “Benign prostatic hyperplasia: an overview,” Int J Urol. 2011; 18(1):3-10.
[3] McVary KT, et al. “Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia,” Urology. 2011; 78(3):720-725.